CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
  
  LEARNING OBJECTIVES

  • Consider the degree to which older patients with multiple myeloma (MM) may be underrepresented in randomized clinical trials, and appreciate the value that examination of real-world evidence may have in treatment planning for this unique population.
  • Customize the selection of first-line therapy for older patients with newly diagnosed MM, considering patient- and disease-related factors, including performance status, comorbidities and cytogenetic risk.
  • Examine clinical trial data and real-world evidence informing the front-line use of various antimyeloma therapies for patients with MM who are not eligible for stem cell transplant, and effectively identify when and how each of these strategies should be integrated into clinical management.
  • Recognize the unique risks and practical considerations associated with long-term maintenance therapy for older patients with MM, and contemplate the potential advantages of an oral proteasome inhibitor in this setting.
  • Appraise published research and other clinical factors in the best-practice selection and sequencing of established regimens and recently FDA-approved novel therapies in the care of older patients with relapsed/refractory MM.
  • Recall the design of clinical trials seeking to enroll older patients with MM in order to counsel appropriate individuals about availability and participation, and recall ongoing efforts to assemble real-world data with those who may not be candidates for protocol treatment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Saad Zafar Usmani, MD, MBA
  Chief of Myeloma Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Endo Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Oncopeptides, Sanofi Genzyme, Seagen Inc, Secura Bio, SkylineDX, Takeda Pharmaceuticals USA Inc, TeneoBio; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seagen Inc, SkylineDX, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Sanofi Genzyme.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Takeda Pharmaceuticals USA Inc.
  
  Release date: January 2022
  Expiration date: January 2023